Evidence map›Paper›PMID 28450929›Full record

ArticleExperimental and therapeutic medicine2017

Effect of intranasal stem cell administration on the nigrostriatal system in a mouse model of Parkinson's disease.

Mohamed Salama, Mahmoud Sobh, Mahmoud Emam, Ahmed Abdalla, Dina Sabry, Mohamed El-Gamal, Ahmed Lotfy, Mahmoud El-Husseiny, Mohamed Sobh, Ali Shalash and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 70 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Nose-to-brain drug delivery: from bench to bedside.Translational neurodegeneration · 2025
    Review
  7. Intranasal administration of mesenchymal stem cells overexpressing FGF21 demonstrates therapeutic potential in experimental Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Mohamed SalamaMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mahmoud SobhMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mahmoud EmamMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Ahmed AbdallaMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Dina SabryMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mohamed El-GamalMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Ahmed LotfyMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mahmoud El-HusseinyMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Mohamed SobhMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
Ali ShalashNeurology Department, Ain Shams Medical School, Ain Shams University, Cairo 11566, Egypt.
Wael My MohamedDepartment of Clinical Pharmacology, Menoufia Medical School, Menoufia University, Menoufia 32811, Egypt.
Mansoura University · EGAin Shams University · EGMenoufia University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide. It affects the locomotor system, leading to a final severe disability through degeneration of dopaminergic neurons. Despite several therapeutic approaches used, no treatment has been proven to be effective; however, cell therapy may be a promising therapeutic method. In addition, the use of the intranasal (IN) route has been advocated for delivering various therapies to the brain. In the present study, the IN route was used for administration of mesenchymal stem cells (MSCs) in a mouse model of PD, with the aim to evaluate IN delivery as an alternative route for cell based therapy administration in PD. The PD model was developed in C57BL/6 mice using intraperitoneal rotenone administration for 60 consecutive days. MSCs were isolated from the mononuclear cell fraction of pooled bone marrow from C57BL/6 mice and incubated with micrometer-sized iron oxide (MPIO) particles. For IN administration, we used a 20 µl of 5×10

Indexed as

animal modelintranasalParkinson's diseasestem cells

Identifiers

PMID28450929
PMCPMC5403256
OpenAlexW2576246889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.